Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
a technology of epidermal growth factor receptor and mass spectrometry, which is applied in the direction of separation of dispersed particles, separation processes, instruments, etc., can solve the problems of poor treatment of nsclc, no substantial benefit, and not always possible depending on the type of cancer patien
Inactive Publication Date: 2011-05-26
BIODESIX
View PDF15 Cites 2 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Enables personalized selection of patients for EGFR pathway treatments initially and during treatment, facilitating timely adjustments and improving treatment outcomes by correlating classification label changes with disease progression, thereby enhancing treatment efficacy and reducing unnecessary exposure to ineffective drugs.
Problems solved by technology
Treatment of NSCLC has been relatively poor over the years.
While surgery is the most potentially curative therapeutic option for NSCLC, it is not always possible depending on the stage of the cancer.
In cancer, however, this signaling goes wrong and the cells continue to grow and divide in an uncontrollable fashion, thereby forming a tumor.
While in some trials EGFR-Inhibitors (EGFR-I) such as those mentioned above have been shown to generate sufficient survival benefit even in unselected populations, in others there was no substantial benefit.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
example
[0047]Methods for how this invention can be practiced will now be described in further detail. As an initial step, a baseline classification of a plasma or serum sample of the patient using mass spectrometry and classification using a training set is obtained, in the manner described in detail in our prior application published as U.S. 2007 / 0231921. The methodology is shown in FIG. 3 described below. If the class label for the patient sample is “good”, the result indicates that the patient is likely to benefit from a drug targeting the EGFR pathway, such as gefitinib, erlotinib or cetuximab. The patient is then prescribed one of these drugs.
[0048]During the course of treatment by administration of an EFGR-I drug, the patient is monitored periodically to determine whether the class label for a serum sample of the patient has changed. A change from “good” to “poor” indicates that the patient may be developing a non-responsiveness to further administration of the EGFR-I drug. This moni...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 12 / 584,594 filed Sep. 8, 2009, which is a continuation-in-part of our prior U.S. patent application Ser. No. 11 / 396,328 filed Mar. 31, 2006, now U.S. Pat. No. 7,736,905. The entire content of the '905 patent is incorporated by reference herein.[0002]U.S. patent application Ser. No. 12 / 584,594 claims priority benefit to U.S. Provisional Application Ser. No. 61 / 191,927 filed on Sep. 12, 2008, which is also incorporated by reference herein.[0003]U.S. patent application Ser. No. 12 / 584,594 is also a continuation-in-part of U.S. patent application Ser. Nos. 12 / 321,392, 12 / 321,393 and 12 / 321,394, each filed on Jan. 20, 2009, the content of each of which is incorporated by reference herein.BACKGROUND[0004]This invention relates to the field of monitoring of treatment of cancer patients with drugs targeting the epidermal growth factor receptor (EGFR) pathway. The monitoring involves ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & AuthorityApplications(United States)
IPC IPC(8): B01D59/44G16B20/00G16B40/10
CPCA61K31/517G06F19/18G06F19/24A61K31/5377Y10T436/24G16B20/00G16B40/00G16B40/10
InventorRODER, HEINRICHTSYPIN, MAXIMGRIGORIEVA, JULIA
OwnerBIODESIX